“Clinical response to Rifaximin amongst irritable bowel syndrome (IBS) patients at tertiary level hospital in Nepal”, J Patan Acad Health Sci, vol. 11, no. 1, pp. 21–26, Jun. 2024, doi: 10.3126/jpahs.v11i1.65652.